InMed Pharmaceuticals Amends Mentari Merger Agreement, Files S-4 for Critical All-Stock Deal
INM has more than doubled off its 52-week low of $0.575.
Summary
InMed Pharmaceuticals announced an amendment to its definitive all-stock merger agreement with Mentari Therapeutics. The amendment clarifies transaction sequencing, the impact of pre-closing financing on the exchange ratio, and tax treatment. This follows the initial merger announcement in May and the S-4 filing on July 2nd, which is a critical step towards closing the deal. For a company facing significant going concern doubt, these clarifications and progress towards the merger are material. The merger is expected to close in Q4 2026, pending shareholder approvals and SEC effectiveness of the S-4.
At the time of this announcement, INM was trading at $1.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $0.58 to $3.28. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: TMX Newsfile.